Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
Cancer Discov. 2013 Jan;3(1):14-9. doi: 10.1158/2159-8290.CD-12-0520.
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
大规模、无偏的组合药物筛选已被用于鉴定有效的基因型选择性治疗组合，这些组合在对临床 BRAF 抑制剂 vemurafenib 耐药的突变 BRAF 和 RAS 黑色素瘤的临床前模型中显示出有前途的活性。
